AI + EXCLUSIVE DATA

AI analyzes funding data you can't access anywhere else

Our proprietary AI monitors 15,000+ companies and identifies which funded companies need YOUR specific solution right now.

10-25 personalized leads daily • 92% average intent score • Smart feed technology

Start with:

✓Flexible Plans • $39/mo or $29/mo annual

✓AI + real-time funding intelligence

✓Never see duplicates in your feed

INDUSTRY FIRST

Apnimed Announces $62.5 Million Series C Financing To Advance Development Of Novel Pharmaceutical Treatments For Obstructive Sleep Apnea (Osa) And Related Sleep Disorders

May 04, 2022•over 3 years ago

Amount Raised

$62.5 Million

Round Type

series c

Cambridge

Description

Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today that it has raised $62.5 million of committed capital in a Series C financing. New investor, Sectoral Asset Management, led the round. Also participating were new investors Alpha Wave Ventures, NexPoint, and others, joining existing investors Morningside Ventures, Seligman Investments, and Tao Capital Partners.

Company Information

Company

Apnimed

Location

Cambridge, Maryland, United States

About

Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea – patients with obstructive sleep apnea could benefit from treatment with a safe and effective oral medication dosed once daily at bedtime. Apnimed’s lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep. Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders. Learn more at apnimed.com or follow us on Twitter and LinkedIn.

FundzWatch™ Score

Medium Activity

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech